Core Insights - Armata Pharmaceuticals reported a quarterly loss of $0.42 per share, consistent with the Zacks Consensus Estimate, compared to a loss of $0.15 per share a year ago [1] - The company posted revenues of $1.16 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 16.01%, and down from $2.97 million year-over-year [2] - The stock has increased approximately 264.9% since the beginning of the year, significantly outperforming the S&P 500's gain of 16.4% [3] Financial Performance - The company has surpassed consensus EPS estimates three times over the last four quarters [1] - The current consensus EPS estimate for the upcoming quarter is -$0.41 on revenues of $1.47 million, and for the current fiscal year, it is -$1.46 on revenues of $5.5 million [7] Market Outlook - The earnings outlook and management's commentary during the earnings call will be crucial for the stock's immediate price movement [3][4] - The Zacks Rank for Armata Pharmaceuticals is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry is currently in the top 34% of over 250 Zacks industries, suggesting a favorable environment for stocks within this sector [8] - Another company in the same industry, Fortress Biotech, is expected to report a quarterly loss of $0.43 per share, with revenues projected to be $23.68 million, reflecting a year-over-year increase of 61.9% [9]

Clinical Trials and Therapeutics - The company has completed three Phase 2 clinical trials, demonstrating the potential of bacteriophage therapeutics as alternatives to traditional antibiotics [116]. - Positive results from the Phase 2a diSArm study for AP-SA02 showed a statistically significant improvement in clinical response rates at 88% compared to 58% for placebo (p = 0.047) [134]. - The Phase 2 Tailwind study indicated a statistically significant reduction in Pseudomonas aeruginosa CFUs at day 17 (p=0.05) and day 24 (p=0.015) for AP-PA02 compared to placebo [123]. - The Phase 1b/2a study for AP-SA02 in complicated S. aureus bacteremia showed a clinical response rate of 100% at the end of study compared to 25% for placebo [134]. - The company is exploring the development of AP-PA02 for acute ventilator-associated pneumonia and severe infections due to multidrug-resistant P. aeruginosa [126]. - The company is committed to advancing phage-based therapeutics into pivotal Phase 3 trials, contingent upon securing additional funding [125]. - The company believes its phage therapies represent a promising means to treat antibiotic-resistant bacterial infections, addressing a growing global health threat [116]. - AP-SA02 demonstrated a higher and earlier cure rate compared to placebo in patients with complicated Staphylococcus aureus bacteremia (SAB) at day 12, with no non-response or relapse observed in the treatment group [137]. Financial Performance - Grant and award revenue for Q3 2025 was $1.2 million, a decrease of 61.0% from $3.0 million in Q3 2024 [149]. - Total operating expenses for Q3 2025 were $8.9 million, down 29.8% from $12.7 million in Q3 2024 [149]. - The net loss for Q3 2025 was $26.7 million, an increase of 386.7% compared to a net loss of $5.5 million in Q3 2024 [149]. - As of September 30, 2025, the accumulated deficit was $377.2 million, indicating ongoing financial challenges [145]. - The company incurred an operating loss of $22.8 million for the nine months ended September 30, 2025, a decrease of 28.5% from $31.9 million in the same period of 2024 [149]. - Interest expense increased by 57.5% to $11.8 million for the nine months ended September 30, 2025, compared to $7.5 million in 2024 [149]. - Research and development expenses decreased by $3.7 million, from $9.5 million for the three months ended September 30, 2024 to $5.8 million for the three months ended September 30, 2025, representing a decline of 38.6% [152]. - Total research and development expenses for the nine months ended September 30, 2025 were $17.7 million, down from $26.0 million for the same period in 2024, a decrease of 32.1% [153]. - General and administrative expenses for the nine months ended September 30, 2025 were $8.9 million, down from $9.9 million for the same period in 2024, a decrease of 10.1% [162]. - The company reported a loss of $14.6 million on the change in the fair value of the Convertible Loan for the three months ended September 30, 2025, compared to a gain of $6.9 million for the same period in 2024 [166]. - The net loss for the nine months ended September 30, 2025, was $49.5 million, adjusted by non-cash items totaling $31.8 million [178]. Funding and Capital Raising - The company plans to raise additional capital through public and private equity, debt financing, and strategic alliances to address liquidity concerns [168]. - The August 2025 Loan was secured for $15.0 million with an annual interest rate of 14.0%, maturing on January 11, 2029 [169]. - The company received an additional $4.65 million in non-dilutive award funding through MTEC, increasing the total MTEC award to $26.2 million [172]. - Cash provided by financing activities for the nine months ended September 30, 2025, was $25.0 million, compared to $34.9 million in 2024 [184]. - The company may seek to raise capital through various sources, including public equity markets and collaborative arrangements [179]. - The company’s ability to raise additional funds may be adversely impacted by worsening global economic conditions and market volatility [175]. Cash and Liquidity - The company has $14.8 million in cash and cash equivalents as of September 30, 2025, which is insufficient to fund operations for the next 12 months [146]. - Cash and cash equivalents were $14.8 million as of September 30, 2025, which is insufficient to fund operations for the next 12 months [168]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $19.1 million, a decrease from $29.6 million in the same period of 2024 [177]. - Net cash used in investing activities was $0.5 million for the nine months ended September 30, 2025, down from $2.0 million in 2024 [183]. - A decrease of $0.4 million in accrued compensation contributed to the changes in net operating assets and liabilities for the nine months ended September 30, 2025 [181]. Agreements and Awards - The company received a Therapeutics Development Award of $5.0 million from the Cystic Fibrosis Foundation, with the final payment of $0.3 million received in January 2024 [120]. - The MTEC Agreement has been modified to increase the total award to $26.2 million, extending the term to September 30, 2025 [141].

Financial Performance - Grant and award revenue for Q3 2025 was $1.2 million, down from $3.0 million in Q3 2024, representing a decrease of approximately 60.0%[6] - Loss from operations for Q3 2025 was approximately $7.8 million, an improvement from a loss of approximately $9.8 million in Q3 2024, indicating a reduction of about 20.4%[8] - The company reported a net loss of $26.7 million for Q3 2025, compared to a net loss of $5.5 million in Q3 2024, reflecting a significant increase in losses[19] - Net loss for the nine months ended September 30, 2025, was $49,501, compared to a net loss of $21,516 for the same period in 2024[21] Expenses - Research and development expenses decreased to approximately $5.8 million in Q3 2025 from approximately $9.5 million in Q3 2024, reflecting a reduction of about 38.2%[7] - General and administrative expenses were approximately $3.1 million in Q3 2025, slightly down from approximately $3.2 million in Q3 2024[8] - Stock-based compensation expense decreased to $1,978 in 2025 from $2,539 in 2024, suggesting a reduction in equity awards[21] - Depreciation expense increased to $1,113 in 2025 from $945 in 2024, indicating higher asset utilization[21] - Non-cash interest expense rose to $11,739 in 2025 from $7,483 in 2024, reflecting changes in financing costs[21] Cash Flow and Liquidity - As of September 30, 2025, cash and cash equivalents increased to approximately $14.8 million from $9.3 million as of December 31, 2024, representing a growth of about 59.1%[9] - Net cash used in operating activities decreased to $19,089 in 2025 from $29,624 in 2024, indicating improved cash flow management[21] - Cash, cash equivalents, and restricted cash at the end of the period totaled $20,146, down from $22,621 in 2024[21] - Cash and cash equivalents at the beginning of the period were $14,771 in 2025, down from $19,243 in 2024, indicating a decline in available liquidity[21] - Changes in operating assets and liabilities improved, with a decrease in cash outflow to $(1,379) in 2025 from $(3,288) in 2024[21] - Restricted cash at the end of the period was $5,390 in 2025, slightly down from $5,480 in 2024[21] Development and Future Plans - AP-SA02 demonstrated a 100% response rate without relapse one week post-BAT and 28 days later, compared to approximately 25% relapse in the placebo group[4] - The company has entered into a secured credit agreement for a loan of $15.0 million, maturing on January 11, 2029, to support the development of AP-SA02[4] - The state-of-the-art cGMP manufacturing facility in Los Angeles is fully operational, supporting future clinical trials and commercialization efforts[4] - The company plans to initiate a Phase 3 study in 2026 for AP-SA02, aiming to address significant unmet medical needs[5] Financing Activities - Proceeds from issuance of term debt amounted to $25,000 in 2025, compared to $34,889 in 2024, reflecting a decrease in financing activities[21]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Qualigen Therapeutics, Inc. (QLGN) increased by 69% to $6.00 - Inhibrx Biosciences, Inc. (INBX) rose by 62% to $46.04 - MidWestOne Financial Group, Inc. (MOFG) gained 33% to $37.87 - Neuphoria Therapeutics Inc. (NEUP) up by 31% to $5.32 - Nextracker Inc. (NXT) increased by 13% to $102.44 - Avalon Holdings Corporation (AWX) rose by 11% to $2.98 - Beyond Meat, Inc. (BYND) up by 9% to $3.12 - SLM Corporation (SLM) increased by 8% to $29.00 - Reborn Coffee, Inc. (REBN) rose by 7% to $2.40 - Oriental Culture Holding LTD (OCG) increased by 5% to $3.55 [3] Premarket Losers - Picard Medical, Inc. (PMI) decreased by 70% to $3.89 - Fusemachines Inc. Common stock (FUSE) down by 17% to $3.29 - American Rebel Holdings, Inc. (AREB) fell by 16% to $3.14 - Armata Pharmaceuticals, Inc. (ARMP) down by 13% to $6.16 - Coya Therapeutics, Inc. (COYA) decreased by 13% to $6.01 - Deckers Outdoor Corporation (DECK) down by 12% to $90.00 - Safe & Green Holdings Corp. (SGBX) fell by 12% to $2.58 - Beasley Broadcast Group, Inc. (BBGI) decreased by 8% to $5.55 - Booz Allen Hamilton Holding Corporation (BAH) down by 7% to $92.73 - Brera Holdings PLC (SLMT) decreased by 6% to $10.67 [4]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Premarket Gainers - Ventyx Biosciences, Inc. (VTYX) increased by 108% to $8.05 - Brera Holdings PLC (SLMT) rose by 49% to $12.50 - Safe & Green Holdings Corp. (SGBX) gained 39% to $3.18 - American Rebel Holdings, Inc. (AREB) up by 26% to $2.71 - Tango Therapeutics, Inc. (TNGX) increased by 18% to $10.25 - Garrett Motion Inc. (GTX) rose by 14% to $14.30 - ETHZilla Corporation (ETHZ) gained 12% to $17.61 - D-Wave Quantum Inc. (QBTS) increased by 11% to $30.40 - IonQ, Inc. (IONQ) rose by 10% to $61.04 - Megan Holdings Limited (MGN) up by 7% to $2.31 [3] Premarket Losers - Splash Beverage Group, Inc. (SBEV) decreased by 21% to $2.06 - Molina Healthcare, Inc. (MOH) down by 18% to $158.44 - SCHMID Group N.V. (SHMD) fell by 18% to $3.18 - Beyond Meat, Inc. (BYND) decreased by 18% to $2.91 - Agencia Comercial Spirits Ltd (AGCC) down by 16% to $5.07 - Super League Enterprise, Inc. (SLE) fell by 13% to $2.25 - Armata Pharmaceuticals, Inc. (ARMP) decreased by 12% to $5.99 - Applied DNA Sciences, Inc. (BNBX) down by 12% to $4.19 - Ribbon Communications Inc. (RBBN) fell by 12% to $3.49 - Tamboran Resources Corporation (TBN) decreased by 11% to $21.81 [4]

Core Insights - Armata Pharmaceuticals, Inc. (ARMP) shares surged 103.2% to $7.05, driven by high trading volume, contrasting with a 13.8% gain over the past four weeks [1][2] - The stock price increase followed positive mid-stage results for AP-SA02, a bacteriophage therapy targeting Staphylococcus aureus bacteremia, showing higher cure rates and zero relapses compared to placebo [2] - The study presented at IDWeek 2025 is the first randomized clinical trial confirming the efficacy of intravenous phage therapy for S. aureus infections, indicating a potential breakthrough in combating antibiotic-resistant bacteria [2] Financial Expectations - The company is projected to report a quarterly loss of $0.42 per share, reflecting a year-over-year decline of 180%, with expected revenues of $1.38 million, down 53.5% from the previous year [3] - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, suggesting that stock price movements may not sustain without earnings estimate revisions [4] Industry Context - Armata Pharmaceuticals operates within the Zacks Medical - Biomedical and Genetics industry, where another company, NeoGenomics (NEO), recently closed 0.9% lower at $10.34, despite a 28.3% return over the past month [4] - NeoGenomics' consensus EPS estimate has increased by 5.7% over the past month to $0.02, representing a year-over-year change of -60% [5]

Core Insights - Armata Pharmaceuticals has reported positive results from its Phase 2a diSArm study of AP-SA02, a bacteriophage therapy for complicated Staphylococcus aureus bacteremia, presented at IDWeek 2025 [1][2][3] Study Overview - The diSArm study was a randomized, double-blind, controlled trial comparing AP-SA02 combined with best available antibiotic therapy (BAT) against a placebo group receiving BAT alone [2][14] - A total of 42 patients were enrolled, with 29 receiving AP-SA02 and 13 receiving placebo, with methicillin-resistant S. aureus (MRSA) identified in approximately 38% of both groups [4][14] Efficacy Results - At day 12, clinical response rates were significantly higher in the AP-SA02 group, with 88% responding compared to 58% in the placebo group (p = 0.047) [6][17] - No patients in the AP-SA02 group experienced non-response or relapse at one week post-BAT or at the end of the study, while the placebo group had a non-response/relapse rate of approximately 25% [7][17] Safety Profile - AP-SA02 was well-tolerated, with treatment-emergent adverse events occurring in 6% of patients in the AP-SA02 group compared to 0% in the placebo group [8][17] - Serious adverse events related to the study drug were not reported [8] Mechanism and Future Directions - The study highlighted the potential of AP-SA02's defined genomic variants to provide rapid, strain-specific responses to S. aureus isolates, suggesting a flexible and adaptive therapeutic approach [10][17] - The results support advancing AP-SA02 into a pivotal Phase 3 trial planned for 2026, pending FDA review [17] Company Background - Armata Pharmaceuticals focuses on developing high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant infections, with a pipeline that includes candidates for various pathogens [16] - The Phase 1b/2a study was partially funded by a $26.2 million award from the Department of Defense [15]

Core Insights - Armata Pharmaceuticals, Inc. (ARMP) is showing strong performance compared to the Medical sector, with a year-to-date return of approximately 68.7% against the sector's average of 3.6% [4] - The Zacks Rank for Armata Pharmaceuticals is 2 (Buy), indicating positive analyst sentiment and an improving earnings outlook [3] - The Zacks Consensus Estimate for ARMP's full-year earnings has increased by 24.7% over the past three months, reflecting stronger analyst sentiment [4] Company Performance - Armata Pharmaceuticals is part of the Medical sector, which includes 960 stocks and currently holds a Zacks Sector Rank of 5 [2] - Within the Medical - Biomedical and Genetics industry, which consists of 472 stocks, Armata Pharmaceuticals ranks 79 in the Zacks Industry Rank, outperforming the industry average return of 9.8% year-to-date [6] Comparison with Peers - Halozyme Therapeutics (HALO) is another stock that has outperformed the Medical sector, with a year-to-date increase of 44.3% and a Zacks Rank of 1 (Strong Buy) [5] - Both Armata Pharmaceuticals and Halozyme Therapeutics are positioned well within their industry and are expected to continue their solid performance [7]

Group 1 - Armata Pharmaceuticals, Inc. (ARMP) has shown strong performance in the Medical sector, returning about 60% year-to-date, significantly outperforming the sector average of -2.3% [4] - The Zacks Rank for Armata Pharmaceuticals is 2 (Buy), indicating positive analyst sentiment and a stronger earnings outlook, with a 24.7% increase in the consensus estimate for full-year earnings over the past 90 days [3] - Armata Pharmaceuticals belongs to the Medical - Biomedical and Genetics industry, which has an average gain of 3.3% this year, positioning ARMP as a better performer within this specific industry [5] Group 2 - The Medical sector includes 973 individual stocks and currently holds a Zacks Sector Rank of 6, reflecting the average strength of the sector [2] - Another stock in the Medical sector, Actinium Pharmaceuticals (ATNM), has also outperformed the sector with a year-to-date return of 27.8% and a Zacks Rank of 2 (Buy) [4][5] - The Medical - Drugs industry, where Actinium Pharmaceuticals is categorized, has 155 stocks and has moved up by 10.1% since the beginning of the year, indicating a relatively strong performance compared to the broader Medical sector [6]

Core Insights - Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing high-purity, pathogen-specific bacteriophage therapeutics for antibiotic-resistant bacterial infections [4] - The company announced a publication in the Journal of Molecular Biology detailing the structure of phage Pa223, which is part of its clinical candidate AP-PA02 [2][3] - AP-PA02 is being developed as a treatment for chronic respiratory infections in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis, showing promising results in two Phase 2 clinical trials [2] Company Overview - Armata Pharmaceuticals specializes in bacteriophage-based technology and is advancing a pipeline of natural and synthetic phage candidates targeting pathogens like Pseudomonas aeruginosa and Staphylococcus aureus [4] - The company emphasizes its commitment to phage therapy, leveraging in-house manufacturing capabilities to support commercialization [4] Scientific Advancements - The publication provides a high-resolution structural analysis of phage Pa223, enhancing understanding of phage biology and its clinical applications [3] - Advances in cryogenic electron microscopy and bioinformatics have enabled near-atomic resolution studies of phage structure, which may inform future therapeutic developments [3]